Key Takeaways ICCM gains FDA authorization to market ProSense for low-risk breast cancer in U.S. women aged 70 .The approval, backed by ICE3 trial data, validates ICCM's ProSense as a minimally invasive alternative.ICCM's clearance opens U.S. sales, strengthens market edge, and supports faster revenue and adoption growth.IceCure Medical (ICCM) recently received FDA marketing authorization for its ProSense cryoablation system, marking the first approval for a minimally invasive treatment of low-risk breast c ...